Digital Genome Market Report 2020 Top Companies- Umbel, BiogeniQ, GenomeMe, NanoString, Illumina and more…

A new market study, titled “Digital Genome Market Research Report – Forecast to 2027”, has been featured on WiseGuyReports.

PUNE, MAHARASTRA, INDIA, November 2, 2020 / — Digital Genome Market

The Digital Genome market report gives an integrated insight into the industry and the core components that influence its performance at the global level. A brief explanation of the chief market offering has been highlighted along with its use in the end-user industry. The chief elements that exist in the market setting and influence the business landscape have been identified and critically examined. On the basis of the detailed assessment, the growth potential of the Digital Genome market at the global level for the forecasted period of 2020 to 2025 has been determined.

The major players in global digital genome market include:
• Umbel
• BiogeniQ
• GenomeMe
• NanoString
• Illumina, Inc

Get Sample Copy of the Report at

Insight into the Digital Genome market

A broad range of factors exist in the industry and influence the business environment. In the Digital Genome market report, the micro and macro factors that exist in the market have been identified and explained. Some of the key factors that have been assessed are the adoption of latest technology the market participants, the fluctuation in the level of supply and demand in the market and the expansion of the global population. The initiatives that have been taken by the government influencing the market have also been examined. Similarly, special attention has been given to the intense market competition as it affects the market performance.

Evaluation of market segments

The Digital Genome market has been segmented on the basis of a broad range of aspects such as the end-use application, type, and geographical regions. A detailed segmentation analysis has been performed to identify the underlying factors that influence the market performance. Some of the chief geographical regions that have been identified and examined in the market report include Latin America, Europe, North America, the Asia Pacific and the Middle East and Africa. The performance of the business participants in each of the geographical regions shapes the ultimate performance of the market at the global level.

Research methodology

An inclusive research of the Digital Genome market has been carried out by the qualified market research team. Strategic approaches and tools have been used for conducting the research and analysis of the market. SWOT analysis has been performed which has highlighted the strengths, weaknesses, threats and opportunities that mold the quality of the market environment. The competitive intensity that is prevalent in the market has been examined by using Porter’s Five Force model.

Players in the market

The key market players that function in the Digital Genome market have been identified. An exhaustive examination of these market players has been performed, including the strategic approaches that are adopted by them to gain an edge over their competitors and reach the vast market audience.

Get Report Summary here

About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

email us here

Source: EIN Presswire

Anti-aging Drugs Market Share,Trends,Supply,Sales,Key Players Analysis,Demand And Forecast 2025

WiseGuyReports.Com Publish a New Market Research Report On –“Anti-aging Drugs Market Share,Trends,Supply,Sales,Key Players Analysis,Demand And Forecast 2025”.

PUNE, MAHARASTRA, INDIA, November 2, 2020 / —
Anti-aging Drugs Market 2020

Description: –

Aging is a natural part of human life. However, recent discoveries indicate that pharmacological approaches used for the improvement and possibly, for the delay of the aging process, might shed a new light on this topic. This might obviously contribute to the extension of the active life of older people and maintenance of their quality of life, which could consequently reduce both social and economic burden of each country, especially the developed ones.

Scope of the Report:

This report focuses on the Anti-aging Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

According to the report, one of the major drivers for this market is Growing disposable income and healthcare expenditure in developing countries. Growing disposable income in developing countries such as India and China has attracted investors from around the world.

Get a Sample Report @

For more information or any query mail at


Merz Pharma
Canbex Therapeutics
Daewoong Pharmaceutical
MMJ PhytoTech
SciVision Biotech
Sun Pharmaceuticals
Suneva Medical
Valeant Pharmaceuticals

The basic information included in the report is effective for a thorough overview of the market profile globally. The reports describe the growth if the Anti-aging Drugs market by portraying the information about the key manufacturing technology and industrial applications. The market has been segmented into various segments based on such effective market information. It also displays the maximum market shares during the forecast period of 2019-2023. And it provides information related to the highly competitive market, market revenue, and the key players of the Anti-aging Drugs markets in a current particular year. The players that are making the Anti-aging Drugs market highly fragmented include global, regional, and country-specific players. And These reports include the details of the key market players for better market knowledge.

This effective market report mainly focuses on the sales of products, product revenues, and product categories. All these focus elements are gaining maximum traction in recent times. It also includes effective information related to the Anti-aging Drugs market and forecasts the growth in the 2023 period. The creation of a solid hold of the market for the forthcoming period is analysed extensively across a broad array of developments. This report studies the value, trends, and the pricing of the global market to predict maximum growth in the future period.

The advance study and suggestions of the market over the forecast period include evaluating various latent growth factors, opportunities, and restrains. This report also provides you with competitive strategies over the various region on the global market. In the global market includes different key players that could tend to maximize the profits of the industries in various regions. Hence these reports aim to include the key market player strategies for assessing the market size and future growth potentials. The effective and detailed market reports offer the industries the best results to benefit different industries in the global Anti-aging Drugs market.

The global Anti-aging Drugs market reports are a compilation of first-hand information. And a major industry analyst does the qualitative and quantitative assessment as per the SWOT model. The strength, weaknesses, opportunities, and threats of the Anti-aging Drugs market are contained in this report. The industries could easily and quickly identify the risk and the opportunity that is involved in the market for effective growth. This in-depth report is extensive research of the primary and secondary market that helps the industries to understand the Anti-aging Drugs market in a better and effective way.

Enquiry About Report @

Table of Contents – Major Key Points

1 Market Overview

2 Manufacturers Profiles

3 Global Anti-aging Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

4 Global Anti-aging Drugs Market Analysis by Regions

5 North America Anti-aging Drugs by Countries

6 Europe Anti-aging Drugs by Countries

7 Asia-Pacific Anti-aging Drugs by Countries

8 South America Anti-aging Drugs by Countries

9 Middle East and Africa Anti-aging Drugs by Countries

10 Global Anti-aging Drugs Market Segment by Type


Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Wise Guy Reports
+1 628-258-0070
email us here

Source: EIN Presswire

Exhalation Technology (ETL) Announces New Clinical Trial for CoronaCheck™ – A Rapid Covid-19 Test for Exhaled Breath

Covid-19 Virus

CoronaCheck™ uses exhaled breath to screen for Covid-19

The CoronaCheck™ device for rapid Covid-19 testing is safe and easy to use

ETL announced a new clinical study with its novel CoronaCheck™ test for Covid-19, aiming for a sub-5 minute test of high specificity and sensitivity

Early results from patients recruited into our clinical study are very promising. CoronaCheck™ provides novel, sensitive and rapid testing for high volume virus testing in a range of environments.”

— Helle Funch Nielsen

CAMBRIDGE, UNITED KINGDOM, November 2, 2020 / — Exhalation Technology (ETL), based in Cambridge, UK, announced the start of a large clinical study on humans with its novel CoronaCheck™ diagnostic test for Covid-19 in exhaled breath condensate (EBC). This is a rapid test (aims for a result in under 5 minutes) of high specificity and sensitivity for Covid-19, meeting the need for efficient and accurate testing in a wide range of environments including hospitals, airports, retail outlets, schools and similar spaces.

ETL have developed CoronaCheck™, a rapid antigen test for Covid-19 virus, exploiting their expertise in exhaled breath diagnostics.
Before the initiation of clinical trials in the UK, CoronaCheck™ has shown very promising results on the laboratory bench:

• It is able to detect as few as <1.5 copies of virus per µl EBC; infected patients are expected to exhale >20 copies per µl
• Test sensitivity is as great as 100% and specificity >90% at test time which aims to be under 5 minutes, yielding a rapid result at point of care
• CoronaCheck™ has been tested with live virus as well as in inactivated virus, and in controlled solutions as well as in “virus-spiked” Exhaled Breath Condensate (EBC)
• Tests with UV-inactivated influenza virus shows that CoronaCheck™ can distinguish between Covid-19 and other viruses such as seasonal flu
• Embedded Bluetooth functionality in CoronaCheck™ enables rapid reporting of results to healthcare authorities and other interested bodies

ETL has announced today that it has opened its human clinical trial program for CoronaCheck™ at the Clinic for Respiratory Medicine based in The Queen Alexandra Hospital, Portsmouth, headed by professor Anoop Chauhan. This will enable a cohort of 300 patients to be tested in a blinded, ethics-approved clinical trial on infected and normal patients; data on up to 150 patients will be available mid Nov 2020.

ETL is seeking one or more global strategic partners with which it can collaborate to exploit its new Covid-19 test. ETL has a strong history in development of diagnostic products based on analysis of the respiratory tract where Covid-19 is prevalent.

ETL has developed CoronaCheck™, a very unique and timely, IP-protected test for rapid detection of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2 also known as Covid-19), using a novel biosensor housed in a safe breath analysis device suitable for rapid point-of-care coronavirus testing. The test measures directly the presence of virus in breath, as opposed to antibodies in the blood.

CoronaCheck™ has safety features to prevent cross-infection and contamination, to measure the SARS-CoV-2 virus in exhaled breath.

Helle Funch Nielsen, CEO of ETL, said “Initial results from patients recruited into our clinical study are very promising. Our CoronaCheck™ test is set to provide novel technology for high volume screening of individuals in a range of environments including schools, airports, shopping centers and sporting events, to name but a few. The technology is entirely innovative and our initial test is based on rapid testing in exhaled breath, a simple and convenient means of sample collection. Our collaboration with Imperial College in London and clinical centers in the UK such as the Clinic for Respiratory Medicine based in The Queen Alexandra Hospital, Portsmouth, is providing rapid proving and validation of this novel approach to Covid-19 testing.”

Stig Lytke Brejl, Director of ETL, said “building on an existing CE marked IVD medical device platform is expected to enable a short time to market while at the same time de-risking the project significantly.”

ETL has partnered with a leading biosensor company for development of the Covid-19 specific biosensor with ETL’s device, CoronaCheck™. The initial product to be launched will measure SARS-CoV-2 in exhaled breath condensate with a readout time aiming to be less than 5 minutes time.

The CoronaCheck™ test is aimed to be available at under $10 or £8 per test.

CoronaCheck™ does not require any laboratory equipment or special handling or training. The biosensor is mounted in a test cartridge which is inserted into the device into which the subject breathes with results obtained in minutes, whereupon the test cartridge is safely discarded and the device is ready for a new test cartridge and subject.

For more information about Exhalation Technology and partnering opportunities for its CoronaCheck™ Covid-19 test, please contact:

Dr. Bill Mason
The Sage Group
The Old Black Barns
Lord’s Lane, Ousden CB8 8TX UK
Tel: +44 (0) 7785 950134


Wayne Pambianchi
The Sage Group Inc.
1802 Route 31 North
#381 Clinton
New Jersey 08809 USA
Phone: +1 908 2306170


Helle Funch Nielsen
Tel: +45 2830 7858

About Exhalation Technology
Exhalation Technology develops breath analysis devices for disease diagnosis, monitoring, and management.

ETL aims to revolutionise respiratory care by providing clinicians the tools they need to provide optimal patient care – with confidence.

By giving clinicians access to information related to underlying causes, ETL can strengthen their decision-making process – and create better outcomes for patients.

Why? Because ETL believe monitoring and managing respiratory diseases should be simple and reliable – for everyone involved. ETL is committed to helping transform the way we diagnose, treat and monitor respiratory diseases.

In improving patient outcomes, we help clinicians meet the challenges and opportunities in an ever-evolving respiratory healthcare world.


About The Sage Group, Inc.
The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million.


Bill Mason
Sage Healthcare Ltd
+44 7785 950134
email us here

Source: EIN Presswire

VR PluraView Monitor in medical applications with Vesalius3D

The innovative, passive-stereo 3D PluraView monitor from Schneider Digital is designed for special use in a wide variety of medical applications.

MIESBACH, BAYERN, DEUTSCHLAND, November 2, 2020 / — The innovative, passive-stereo 3D PluraView monitor from Schneider Digital is designed for special use in a wide variety of medical applications. With additional VR tracking capability, it is the perfect VR-stereoscopic visualization partner for Vesalius3D – including head-tracking and gesture control via track-pens or -spheres as well as foot switches for zoom functions.

Combined with Vesalius3D, it offers the medical industry a turnkey 3D workplace solution to analyze volumetric medical data conveniently and efficiently and to present it accordingly – in the highest resolution, flicker-free, in a normal office daylight environment. Areas of application are for instance in medical diagnoses, surgery planning, anatomical 3D imaging (X-ray CT, MRI), 3D printing or the evaluation of other, visual medical data for instance ultrasound.

Vesalius3D is an extremely user-friendly application for the visualization of patient-specific anatomical structures from standard DICOM medical data:

• 3D-stereo visualization – enables you to look into the virtual, digital body of a patient.
• Seamless integration of 2D and 3D data: Using images in 2D or 3D, doctors can quickly and reliably identify their patients' problem.
• No special scans required: processes standard medical image formats (CT, MRI, ultrasound).
• Intuitive VR interaction: Grip and position the 3D model with one hand, operate the tools with the other hand, view a model from all sides via head tracking.

Josef Johannes Schneider
Schneider Digital Josef J. Schneider e. K.
+49 8025 99300
email us here

VR PluraView – PS Tech Real Object Tracking Healthcare

Source: EIN Presswire

Lymecycline reverses acquired drug resistance in non–small-cell lung cancer



VulcanChem – Global Leading Supplier of Research Chemicals

VulcanChem – Global Leading Supplier of Research Chemicals

A study finds Lymecycline reverses acquired EGFR-TKI resistance in non–small-cell lung cancer by targeting GRB2.

PASADENA, CALIFORNIA, UNITED STATES, November 2, 2020 / — In a recent study, researchers from China discovered lymecycline has the ability to reverse acquired EGFR-TKI resistance in cell lines and animal models, suggesting a potential therapeutic agent for acquired EGFR-TKI resistant non-small-cell cancer (NSCLC) and improve the prognosis of patients.

NSCLC is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC), which accounts for about 85% of all lung cancers. Epidermal growth factor receptor (EGFR) mutations are found in 10–35 % of NSCLCs and first- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were first-line treatments (e.g. Icotinib) for patients with this mutation. However, about 30 % of responders relapsed within six months because of acquired resistance. Acquired EGFR-TKI resistance limits the therapeutic benefit of TKIs. To discover drugs that reverse this effect, researchers from the First Hospital of China Medical University used Connectivity Map (CMap) to performs computational drug repositioning using a reference database based on genes and pathways related to NSCLC and its treatments. They discovered that regulated gene expression and reversed acquired EGFR-TKI resistance but has not been previously studied in cancer treatment. To confirm the findings of the network pharmacology studies, two Icotinib resistant cell lines were constructed and lymecycline’s ability to suppress the proliferation of Icotinib resistant cells in vitro and in vivo was then evaluated.

Here is what they found: combined Lymecycline and Icotinib treatment produced a synergistic effect and induced apoptosis. Cell proliferation in resistant cancer cells was significantly inhibited by the combined Lymecycline and Icotinib treatment in mouse models. It is suggested that lymecycline inhibited the resistance of the cell cycle to EGFR-TKI and induced apoptosis in NSCLC by inhibiting EGFR phosphorylation and GRB2-mediated AKT/ERK/STAT3 signaling pathways. Growth factor receptor-bound protein 2 (GRB2) is an EGFR-binding adaptor protein essential for EGFR phosphorylation and regulation of AKT/ERK/STAT3 signaling pathways. Lymecycline targeted GRB2 and inhibited the resistance of the cell cycle to EGFR-TKI, arresting disease progression, and inducing apoptosis in cancer cells.

According to experts at VulcanChem, lymecycline is a semisynthetic derivative of tetracycline and is approximately 5000 times more soluble along with being unique among tetracyclines. It is considered as a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. Lymecycline binds to the 30S ribosomal subunit, preventing amino-acyl tRNA from binding to the A site of the ribosome, which prevents the elongation of polypeptide chains. This results in bacteriostatic actions, treating various infections. Lymecycline is lipophilic and easily crosses the cell membrane and passively diffuses through bacterial porin channels. In general, tetracycline cytotoxicity induces apoptosis in lymphocytes, osteosarcomas, and prostatic cancers and may prevent metastasis.

Valerie Walters
email us here
Visit us on social media:

Source: EIN Presswire

America Please Think Twice Before Voting For Trump. The Only Expert He Listens To Is His Own Insane Gut

Know the Level of Your brain You Are Living From.

Know and Harness the Difference Between Your Brain and Mind.

This is the truth about Trump.

Emotional health is the panacea for a wise America.

Emotional intelligence comes from emotional health.

Trump lives in his own reality that is generated by his insanity. How he has handled the coronavirus should be proof enough that he ignores science over his gut

We must make sure we chase insanity out of the White House on Nov. 3rd and take steps to chase out insanity from all American lives. We can and must create an emotionally super healthy & wealthy US.”

— Sajid Khan

HOUSTON, TEXAS, USA, November 1, 2020 / — The reason why I have published hundreds of blogs, comments, articles explaining that Trump is unfit to be president is two-fold. To wake up America to the blunder of voting Trump into the White House. We must make sure Trump is not voted in once again.

Trump is emotionally challenged and just as I had predicted he has made a mess of everything especially the handling of the corona response. It is estimated that his rallies alone have caused the spread of the virus to over 70,000 people and has caused 700 deaths. The question is how long can we afford insanity as our leader?

The second and even more essential reason is to make our experts and leaders take action on the fact that Trump is just the symbol in chief of America's #1 problem; America is an emotionally challenged country by far. Our society is a mess because our emotional health is a mess as there is no focus on emotional health. Emotional health is misdefined as mental health; even when these are separate entities. The Social Progress Institute that has several Nobel Prize winners is now asking for similar action. They are even saying that our social decline has accelerated due to Trump's mishandling.

Our #1 problem needs fixing/healing. I have even innovated the path to an emotionally super healthy America. Let's start by asking and answering the right questions.

Wisdom is above all selfless love and just as love is an emotion so is wisdom. Wisdom is an emotion that is effortlessly generated by an emotionally healthy brain. In fact, wisdom springs from emotional health. Wisdom is the smoke where emotional health is the fire. Wisdom is so very hard to create as it is like our experts try to generate smoke without lighting the fire. My wisdom formula even has huge America changing applications as it will create a newer wisdom industry:

There is a very simple trick to creating a wise/emotionally super healthy America.

We need to shift the focus from emotional intelligence and wisdom to emotional health:

Emotional health must be clearly defined. We cannot afford a president who denies his own emotional sickness and will not even heal himself. So how will Trump take care of an emotionally challenged America?

Sajid Khan, President
4th R Foundation
+1 201-450-8098
email us here

My hypothesis that has applications in education, health, society, happiness, prosperity, relationships, peace etc.

Source: EIN Presswire

The 4th R Foundation is honored to endorse Booker for the senate and Gottheimer and Pascrell for congress

Wisdom Education is Brain Health Education; Where Wisdom Land is a Start...

Our Education System Has Cutting Edge Mind Education While Brain Education Is Under the radar Screen.

This is the truth about Trump.

Brain and mind are two separate entities and so mind and brain education are different.

The quality of the self-image determines the quality of life for individuals, groups and countries.

Given the divisions, we will need extraordinary talent to get any senate and congress work done. Booker, Gottheimer, and Pascrell are perfect for the job.

One of the top priorities has to be bringing the country together and for that Booker, Gottheimer, and Pascrell are indispensable assets. They need to be reelected for the greater good.”

— Sajid Khan

RIDGEFIELD PARK, NJ, USA, November 1, 2020 / — One of the biggest problems that the Biden-Harris team needs to solve is the big divide between the right and left. Biden will need on his team, leaders like Booker, Gottheimer, and Pascrell. They are all past masters of working with friends and colleagues from both sides of the aisle. 

In these critical times when our Republicans and Democrats are shouting over each other and fighting for their own direction to take the country, we need leaders who have the skills to bring the two opposing factions onto the same page. For Biden to accomplish the quality of healing needed he needs team members who think and work like him to make compromises with the right.

When we recommend candidates we test the competence of their brains and minds separately, brains for emotional health, which is none other than wisdom and minds for professional expertise. All three of these leaders pass with flying colors. 

It is essential that we elect only emotionally super healthy candidates. Look at the mess and destruction the election of Trump has caused. He has an OK professional mind but his brain is insane. Minds every president has to hire but the emotionally healthy brain every leader has to have his own as all policy decisions are emotional decisions. Trump is totally unfit in the emotional health department.

I would like to ask Trump's base. 'When Trump cannot even heal his own emotional health how is he going to provide emotionally healthy (wise) leadership? When Trump cannot master his own insane gut, his master, then how will he master the many problems facing the country?' IF he wins the next term it will be more of the same. His insanity overruling all science! Trump's insane gut will remain the only expert in the room. Trump's insane gut already 'knows' all there is to know. Trump has no plan and if he wins it will be more of the same mess.

Not only do we need to elect Biden and Harris who are super qualified in brain and mind, but we also need Booker, Gottheimer, and Pascrell, and the like, to act as foot soldiers in the senate and congress to get the agenda passed by working across the aisle.

In fact, all the more reason we need to elect Biden is that his team will consist of cutting edge political stars like Booker who will be big on not only passing legislation they will bring their exceptional professional and scientific expertise to help solve problems faced by the nation.

In contrast, Trump's team consists of just his own self and his insane gut. He recruits his team to be only lapdogs, who if they even slightly differ with his insane gut are fired. Lapdogs like McConnell and Graham who knowingly lie to cover up Trump's insanity must be punished at the polls.

All these three do their researched homework well and like Biden, they are always looking for more and more innovations. 

So it is a matter of electing sanity over insanity. Wisdom over ignorance. Love over hate. Unity over division. Science over myth. Well researched plans over haphazard and insane gut reactions. A cutting edge team over Trump and his insanity team.

So to beef up the Biden-Harris team please vote for Biden and the likes of Booker, Gottheimer, Pascrell, and other similar caliber candidates. 

Please make America America again by throwing out insanity from the White House and by voting in wisdom.

I have my own unique formula for wisdom with its own trillion-dollar applications.

I have been an activist for emotional health (EH)/wisdom for the last 50 years and now the Social Progress Institute that consists of several Nobel Prize winners is calling for similar activism. They are saying that our social standards are declining and failing and they are even saying that Trump is accelerating the decline.

Sajid Khan, President
4th R Foundation
+1 201-450-8098
email us here
Visit us on social media:

My hypothesis.

Source: EIN Presswire

Advocacy Group Hosts Demonstration at the US Capitol for Dismissed Measure Supporting Children Facing A Cruel Death

One of 100 children diagnosed with DIPG could live to be an adult.

DIPG Advocacy Group in front of Cannon House Office Building

Paul Miller, Janet Demeter, William Psar, and Elizabeth Psar in front of Cannon House Office Building


The DIPG Awareness Resolution brings attention to children fighting for their lives; House leadership continues to dismiss them on a technicality.

These kids die a horrific death of suffering that is not necessary; we have the technology today unlike 58 years ago when Neil Armstrong’s daughter died of DIPG. People just don’t know.”

— Janet Demeter, co-founder of DIPG Advocacy Group

SANTA CLARITA, CA, USA, November 1, 2020 / — DIPG Advocacy Group, a coalition of pediatric brain cancer foundations and individual childhood cancer advocates, formed in late 2017 expressly for the purpose of supporting the National DIPG Awareness Resolution in the House of Representatives. Currently designated H. Res. 114, the resolution was first introduced in 2016, again in 2017, and finally in the 116th Congress on February 8, 2019 by Jackie Speier (D-CA-14) and David Joyce (R-OH-14) to draw attention to DIPG, pediatric brain cancer, and the chronic lack of adequate funding into pediatric cancer research for effective treatments.

Currently, the Resolution has the support of over 180 lawmakers signed as cosponsors, and the group’s goal is to reach 218 cosponsors by December 1st as a point in their case to House leadership. “Sadly, we have to make the case that our children are a worthy exception to a rule in the House restricting due process for resolutions which designate a ‘commemorative’ day, because of excessive overuse in the 1990s. Only one exception has ever been made since then, in 2016 for Patriot’s Day. All we are asking is for the acknowledgement of our Representatives in Congress–our most direct representation in the federal government,” explains Janet Demeter, the group’s founder, with Jack’s Angels foundation in Agua Dulce, CA. “We’re not asking them to change the rules, just to make an exception for these children in their most urgent need who have been neglected for decades, and who have so little time to find a cure. Until we can create more impactful legislation to fund research, H. Res. 114, our #Moonshot4Kids, could help speed financial support and scientific collaboration, accelerating effective therapies to save lives.”

The #Moonshot4Kids Rally for the Children is scheduled for the west lawn of the US Capitol on Tuesday, Nov. 17 at 12 noon, with a restricted total number of 50 to attend with masks and social distancing, and registration required to physically attend, with the event live-streamed on youtube and facebook for the public. The presentation will face eastward toward the Capitol Building, beneath the Speaker’s Office balcony, including pre-recorded video and live testimonials to the national, and international community’s support for children with brain cancer.

Co-founder Elizabeth Psar, CEO of the Julia Barbara Foundation in Knoxville, TN, explains, “DIPG is the 2nd most common brain tumor in children and is responsible for the majority of childhood deaths due to brain tumors. Most people do not think of brain cancer when they think of childhood cancer. It’s the most prevalent cancer in children and leads in childhood cancer deaths. We need this awareness resolution and awareness day, May 17, to alert and educate the public about it, our lawmakers, and clinicians. We’re discovering them too late, or at autopsy because we just don’t talk about it, and nobody knows. Awareness can help save lives today.” The third of the founders, Paul Miller from Littleton, CO interjects, "we're not even asking for money; just a day. A day for these kids fighting to stay alive, to fundraise, to bring hope, and to let them know we care."

In making their case, the legislative protocol originally referenced for the Patriot’s Day resolution is in effect today and viewable on Majority Leader Steny Hoyer’s website, stating, “A resolution of bereavement, or condemnation, which calls on others to take a particular action, is eligible to be scheduled for consideration.” Demeter explains, “all we’re asking for is this consideration; these kids die a horrific death of suffering that is not necessary; we have the technology today unlike 58 years ago when Neil Armstrong’s daughter died of DIPG. People just don’t know. We’ve been a voiceless community, with families too devastated to conceive of hopeful advocacy. We’re told our children’s lives don’t matter enough for research funding and to ‘go make memories’. We’re asking our Members of Congress for help, and are grateful for the enormous show of support from so many Representatives, and from the Senate. If only the House leadership would just allow a pathway for it to have a moment.”

In its language, the simple House Resolution suggests that federal funding be increased for pediatric cancers in general, and that pediatric and high-mortality rate cancers be given greater consideration in the research grant process. For more information about this event, and registration, visit the events pages at on November 4, 2020 for updates.

Janet Demeter
DIPG Advocacy Group
+1 661-977-3125
email us here
Visit us on social media:

Source: EIN Presswire